© IceCure Medical PR
CAESAREA, Israel – IceCure Medical Ltd. (NASDAQ:ICCM), a company specializing in cryoablation technologies, today announced that it has received a Notice of Grant from the Japan Patent Office for a patent titled “Cryogen Flow Control.”
This patent, which is expected to remain valid until 2042, is part of IceCure's strategy to improve the precision and effectiveness of cryoablation procedures, a minimally invasive method of destroying tumors by freezing.
The ProSense® system, developed by IceCure, uses liquid nitrogen to freeze and eradicate both benign and malignant tumors, including those found in the breast, kidney, lung and liver. The system is designed to be easy to use and transportable, enabling rapid in-office procedures for breast tumors, potentially reducing recovery times, pain, and surgical risks for patients.
The newly granted patent focuses on regulating cryogen flow based on sensor data, ensuring that the desired temperature is constantly maintained at the tips of catheters and probes during cryoablation.
This control is essential for the safety of the surrounding tissues and the overall success of the procedure. Advanced features of the system may include support for navigation and mapping within the patient's body, expanding the technology's potential applications.
Eyal Shamir, CEO of IceCure, expressed confidence that the new patent will play an important role in advancing the field of cryoablation by enabling more precise navigation and mapping, which could lead to broader clinical applications. The company's partnership with Terumo, its distributor in Japan, is expected to strengthen IceCure's presence in the Japanese market.
The patent is still pending approval in other major markets, including the European Union and the United States. IceCure's intellectual property portfolio now includes 42 issued and licensed patents, reflecting its commitment to innovation in the field of cryoablation technology.
The information in this article is based on a press release from IceCure Medical.
This article was generated with the support of ai and reviewed by an editor. For more information consult our T&C.
